The Medicines Company Angiomax
Executive Summary
FDA issues "approvable" letter May 11 for bivalirudin as an anticoagulant for patients with unstable angina undergoing percutaneous transluminal coronary angioplasty. In October 1998, FDA's Cardiovascular and Renal Drugs Advisory Committee declined to recommend the anticoagulant, formerly Hirulog, for approval (1"The Pink Sheet" Nov 2, 1998, p. 19)
You may also be interested in...
TMC Angiomax Launch Projected For Mid-2001 With Innovex Sales Force
The Medicines Company expects to launch its anticoagulant Angiomax (bivalirudin) by mid-2001 with the help of Quintiles' contract sales division Innovex.
TMC Angiomax Launch Projected For Mid-2001 With Innovex Sales Force
The Medicines Company expects to launch its anticoagulant Angiomax (bivalirudin) by mid-2001 with the help of Quintiles' contract sales division Innovex.
Medicines Company To Undertake Two Hirulog Studies After Cmte. Rejection
The Medicines Company is prepared to go ahead with two previously planned studies for Hirulog (bivalirudin) following an FDA advisory committee rejection of the anticoagulant.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: